Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | CCN(CC)C(=O)[C@@H](C)n1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |r,wU:7.7,(15.06,-9.1,;16.59,-9.09,;17.36,-10.41,;16.6,-11.73,;17.37,-13.05,;18.89,-10.4,;19.66,-11.72,;19.64,-9.07,;18.87,-7.76,;21.18,-9.07,;22.09,-7.81,;23.56,-8.28,;24.89,-7.51,;26.23,-8.28,;27.56,-7.5,;26.23,-9.83,;27.57,-10.6,;28.9,-9.82,;24.9,-10.6,;24.89,-12.14,;23.56,-12.9,;23.55,-14.44,;24.89,-15.21,;24.88,-16.76,;26.23,-14.44,;26.22,-12.9,;27.56,-12.13,;23.57,-9.83,;22.1,-10.32,;21.63,-11.78,)| |